

QUALITY OF LIFE, SALIVARY CORTISOL AND ATOPIC DISEASES IN YOUNG CHILDREN

Running head: Quality of life, cortisol and allergic disease in young children

Manuscript word count: 3971

Abstract word count: 350

Table count: 6

Figure count: 4

Leif Bjarte Rolfsjord, MD^{1,2,3}, Håvard Ove Skjerven, MD, PhD^{2,3}, Egil Bakkeheim MD, PhD², Teresa Løvold Berents, MD, PhD⁴, Kai-Håkon Carlsen MD, PhD^{2,3}, Karin C Lødrup Carlsen^{2,3}MD, PhD

Affiliations:

1 Department of Paediatrics, Innlandet Hospital Trust, Elverum, Norway

2 Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway

3 Institute of Clinical Medicine, University of Oslo, Norway

4 Department of Dermatology, Oslo University Hospital, Norway

Address of correspondence to:

Leif Bjarte Rolfsjord, Department of Paediatrics, Innlandet Hospital Trust, P.O. Box 407, NO-2418 Elverum Norway e-mail: rolfl@sykehuset-innlandet.no

ABSTRACT

Background

Children with atopic disease may have reduced health-related quality of life (QoL) and morning cortisol. The link between QoL, cortisol and atopic disease is unclear. We aimed to determine if QoL was associated with morning salivary cortisol at two years of age, and if asthma, atopic dermatitis and/or allergic sensitisation influenced this association. Secondly, we aimed to determine if QoL at one year of age was associated with salivary cortisol one year later.

Methods and findings

From the Bronchiolitis All SE-Norway study, enrolling infants during hospitalisation for acute bronchiolitis in infancy (bronchiolitis group) and population based control infants (controls), we included all 358 subjects with available Infant Toddler Quality of Life Questionnaire™ (ITQOL) consisting of 13 domains, and morning salivary cortisol measurements at two years of age. Additionally, QoL nine months after enrolment was available for 289 of these children at one year of age. Recurrent bronchial obstruction was used as an asthma proxy. Atopic dermatitis was defined by Hanifin and Rajka criteria and allergic sensitisation by a positive skin prick test. Associations between QoL and cortisol were analysed by multivariate analyses, stratified by bronchiolitis and control groups due to interaction. At two years of age, QoL was significantly associated with 8/13 QoL domains in the bronchiolitis group, but only with General health in the controls. The associations in the bronchiolitis group showed 0.06-0.19 percentage points changes per nmol/L cortisol for each of the eight domains (p-values 0.0001-0.034). The associations for all domains remained significant, but were diminished by independently including recurrent bronchial obstruction and atopic dermatitis, but remained unchanged by allergic sensitisation. In the bronchiolitis group only, 8/13 age and gender adjusted QoL domains in one-year old children were significantly associated with cortisol levels at two years (p= 0.0005-0.04).

Conclusions:

At two years, most QoL domains were associated with salivary cortisol in children who had been hospitalised for acute bronchiolitis in infancy, but for one domain only in controls. The associations were weakened, but remained significant by taking into account asthma and atopic dermatitis. The QoL in one-year old children was associated with salivary cortisol 10 months later.

Abbreviations:

QoL – Health related quality of life

ITQOL – The Infant Toddler Quality of Life Questionnaire

AD – Atopic dermatitis

Key words: Quality of life, morning salivary cortisol, allergic disease, children, acute bronchiolitis

CONTRIBUTIONS BY EACH AUTHOR

Leif Bjarte Rolfsjord, M.D., main author, has given substantial contributions to the conception and design of the work, acquisition of the data, analysis and interpretation of the data, drafted the work, finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Håvard Ove Skjerven, M.D., Ph.D. is PI of the Bronchiolitis study, has given substantial contributions to the conception and design of the work and contributed to acquisition of the data for the work. He has revised it critically for important intellectual content. He has finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Egil Bakkeheim, M.D., Ph.D. has given substantial contributions to the conception and design of the work, especially morning salivary cortisol data and contributed to analysis of the data for the work. He has revised it critically for important intellectual content. He has finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Teresa Løvold Berents, M.D., Ph.D. has given substantial contributions to the conception and design of the work and contributed to acquisition of the data for the work, especially of atopic dermatitis data. She has revised it critically for important intellectual content. She has finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Kai-Håkon Carlsen, M.D., Ph.D. has given substantial contributions to the analysis and interpretation of the data for the work. He has revised it critically for important intellectual content. He has finally

approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Karin C. Lødrup Carlsen, M.D., Ph.D. has given substantial contributions to the conception, design, analysis and interpretation of the data of the work. She has given substantial contributions to drafting the work and has revised it critically for important intellectual content. She has finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflicts of interests: Each named author has reported no conflicts of interest.

INTRODUCTION

Reduced health related quality of life (QoL) has been reported in children with asthma (1, 2) and atopic dermatitis (AD) (3) as well as in infants admitted to hospital for acute bronchiolitis (4-8), a disease known to increase the risk of later asthma (9, 10). Also, the generic Infant Toddler Quality of Life Questionnaire™ (ITQOL) has shown reduced QoL in young children with obstructive airways disease (11), AD (7) and other diseases (5), while reduced QoL also may be associated with psychological and physical stress (12).

Acute bronchiolitis may represent acute stress to the infant, as we recently showed that infants with moderate to severe acute bronchiolitis had higher morning salivary cortisol than healthy infants (13), in line with the higher morning salivary cortisol observed in children and adults during acute stress (14). Furthermore, the severity of acute bronchiolitis has been associated with plasma cortisol suppressing the T-helper cell type 1 (Th1) immune response (15), possibly leading to a shift to a Th2 response in acute bronchiolitis through inhibition of the interferon gamma response acting directly on T cells or indirectly through IL-12. Glucocorticoids may stimulate the secretion of IL-4 and IL-10, enhancing the Th-2 response, and stimulate Th2-cells directly (16), as well as possibly suppressing Th2-inflammation (17).

The reduced basal morning cortisol levels observed in children with asthma, also without concurrent use of inhaled corticosteroids (ICS) (18), may on the other hand indicate chronic immunological stress. The subsequent blunted cortisol responses to acute stress in subjects with asthma related to a disturbance of the hypothalamus-pituitary-adrenal (HPA) axis differs from the chronic stress in non-atopic children that can lead to a higher cortisol response (19, 20). Similarly, a blunted cortisol response to acute stress has been suggested in children with AD (21). On the other hand, a higher morning salivary cortisol was observed in two year old children with AD and allergic sensitisation, while a non-significant tendency to lower cortisol was found in children with at least three wheeze episodes (22).

In adults with poorly controlled asthma, both reduced morning salivary cortisol as well as reduced QoL have been found (23), while possible links between QoL, cortisol and atopic disease in children are not known.

Morning salivary cortisol, reflecting the non-protein bound fraction of serum cortisol (24, 25) was recently shown to be similar in two year old children with and without acute bronchiolitis in infancy (13) with values ranging from 2.5 to 189.0 nmol/L, and with higher levels in girls than in boys.

Based upon our previous findings of high morning cortisol levels during acute bronchiolitis but with levels at two years of age similar to those of controls (13), we hypothesised that *low* cortisol levels in periods without acute illness may contribute to development of asthma. We further hypothesised that reduced QoL some months after severe acute illness in early life may be a marker of chronic stress, with subsequent lower future salivary cortisol levels.

We therefore primarily aimed to determine if QoL was associated with morning salivary cortisol at two years of age, and if asthma, atopic dermatitis and/or allergic sensitisation modified this association. Secondly, we aimed to determine if QoL at one year of age was associated with salivary cortisol at two years.

MATERIALS AND METHODS

Study design

From the source population of 644 children included in the Bronchiolitis ALL SE-Norway study enrolling infants who were hospitalised for acute bronchiolitis and controls recruited from a general population (7), we included all 358 children with available salivary cortisol and QoL at 24 months of age. The bronchiolitis group consisted of 203 infants with moderate to severe acute bronchiolitis at inclusion, and 155 were controls. For details, see figure 1 and Supporting Information.

Legend Figure 1:

The figure outlines the number of infants enrolled in the Bronchiolitis All SE-Norway study (top, n=644) who were subsequently included in the present study (n=358) for analyses based upon available

Quality of life (QoL) and/or salivary morning cortisol at 24 months of age. The QoL questionnaires were completed nine months after enrolment at approximately 14 months of age (QoL₁) as well as at the time of the clinical examination at 24 months of age (QoL₂).

Investigations at enrolment and at two years of age included clinical assessment, structured parental interviews and morning salivary sampling for cortisol, whereas skin prick test (SPT) for common inhalant and food allergens was performed at two years only. Quality of life questionnaires were completed nine months after enrolment (QoL₁) (7, 8) and at two years of age (QoL₂).

Caregivers of all children signed the informed written consents prior to study enrolment. The study was approved by the Regional Committee for Medical and Health Research Ethics and The Norwegian Data Protection Authority and registered in the Norwegian bio bank registry. The randomised clinical trial part of the study was registered in Clinical Trials.gov, no. NCT00817466 (26).

Study subjects

The mean (range) age of the 358 children in the present study was 5.2 (0.2-13.4) months at enrolment and 24.2 (17.6-34.7) months at the two-year investigation. The children in the bronchiolitis group compared to controls were shorter, more often exposed to second-hand smoke at inclusion and their parents had lower income, lower educational attainment and less often allergic rhinitis or AD (Table 1).

Table 1

Characteristics and asthma risk factors of the children at two years of age. All data are given as n and %, unless otherwise stated. The control group is the group from the reference population.

	Bronchiolitis group N=203	Control group N=155
Boys n (%)	117 (57.6%)	89 (57.4%)
Age months, mean (SD)	24.2 (3.2)	24.3 (3.7)
Weight kg, mean (SD)	13.2 (1.6)	12.9 (1.5)
Length cm, mean (SD)	87.0 *** (4.1)	88.7(4.2)
Breastfeeding at enrolment n (%)	149 (73.4%)	122 (78.7%)
Second-hand smoke exposure in infancy n (%)	25 (14.4%)**	5 (3.3%)
Second-hand smoke exposure at 2 years	5 (2.5%)	1 (0.7%)
Atopic manifestations defined at 2 years		
At least one n (%)	103 (50.7%)	37 (23.9%)
Two or more n (%)	19 (9.4%)	25 (7.3%)
rBO (at least 3 wheeze episodes) n (%)	98 (48.3%***)	22 (14.2%)
Atopic dermatitis at 2 years n (%)	30 (14.8%)	25 (16.1%)
Allergic sensitisation ¹ n (%)	17 (8.4%)	11 (7.4%)
At least one parent asthma n (%)	35 (22.2%)	46 (29.7%)
At least one parent AD n (%)	33 (18.2%*)	46 (29.7%)
At least one parent allergic rhinoconjunctivitis n (%)	62 (34.4%***)	84 (54.2%)
Higher education mothers ² n (%)	122 (70.1%***)	142 (91.6%)
Higher education fathers ² n (%)	100 (57.8%***)	129 (83.8%)
Income mothers ³ , mean (SD)	1.92 **	2.13
Income fathers ³ , mean (SD)	2.32 ***	2.59
Caucasian mother n (%)	189 (93.6%)	147 (94.8%)
Caucasian father n (%)	191 (95.0%)	143 (92.3%)

¹Allergic sensitisation was define by at least one positive skin prick test to common inhalant and food allergens

²Higher education at least three years after secondary school

³Annual income before tax. 1: <300.000 NOK. 2: 300.000-500.000 NOK. 3: >500.000 NOK.

* p<0.05 ** p<0.01 ***<0.001

Methods

Atopic manifestations determined at two years of age, consisted of recurrent bronchial obstruction (rBO) as a proxy for asthma, atopic dermatitis and allergic sensitisation.

Recurrent bronchial obstruction was defined as at least three parentally reported episodes of wheeze at two years of age, in line with previous reports (27), with acute bronchiolitis included as one episode.

177 *Atopic dermatitis* was defined based upon the modified Hanifin and Rajka's criteria (yes or no) (28),
178 and severity by the SCORing AD index (SCORAD) (see Supporting Information for details).

179 *Allergic sensitisation*, determined by SPT using 17 common inhalant and food allergens with Soluprick
180 SQ allergen extracts, ALK, Hørsholm, Denmark, was defined as positive with at least one mean wheal
181 diameter at least 3 mm greater than the negative control. Further details are given in the Supporting
182 Information.

183 *Morning salivary cortisol* was sampled by the parents on the first morning after enrolment in the
184 bronchiolitis group, otherwise at home and brought to the investigation centre. Two Sorbette®
185 hydrocellulose microsponges were applied in the child's mouth as soon as possible after their child's
186 first awakening after 6:00 a.m., before the first meal, and placed in appropriate prepared containers, as
187 described elsewhere (13). The samples were stored at -86°C and later analysed at Karolinska Institutet,
188 Stockholm, with radioimmunoassay with monoclonal rabbit antibodies Codolet, France).

189 *The Infant Toddler Quality of Life™ Questionnaire (ITQOL-97)* (11) completed by the parents included
190 97 questions within 13 domains scored from 0 (worst) to 100 (best), with no overall score. Accordingly,
191 a change in QoL score is equivalent to the percentage point score change. The Overall health domain
192 consisted of only one item: Is your child's health excellent, very good, good, fair or poor? In line with
193 others (29) and as previously reported (7, 8), with permission from the copyright holder, we recoded the
194 domain Change in health from the original scores from 1-5 to 0-100 (zero meaning worst deterioration
195 of health from one year ago, 50 meaning no change). Four domains (Change in health, General
196 behaviour, Overall behaviour and Getting along) were recorded in children older than 12 months only
197 (7).

198 **Study outcomes and explanatory variables**

199 The main outcome for our primary aim, QoL₂, was reported by quantitative values per domain, and
200 secondarily by the number of domains with significantly reduced QoL₂ scores.

The main explanatory variables for the primary aim were morning salivary cortisol, and the three atopic manifestations rBO, AD and allergic sensitisation at two years of age. Further analyses reported in Supporting Information substituted the respective atopic manifestations by quantitative measures, i.e. the total number of wheeze episodes, the AD severity score SCORAD and the sum of SPT wheal diameters for influence on the associations between morning salivary cortisol and QoL₂. The main outcome of the secondary aim was morning salivary cortisol, with QoL₁ as the explanatory factor.

Statistical analysis

The bronchiolitis and control groups were compared by Pearson's chi-square tests for categorical data and Student's T- test for normally distributed numerical data, and otherwise with Welch test, unless otherwise stated.

Due to non-normality of results and residuals, we used linear robust regression by Huber's M method (30), for analyses including QoL and cortisol. To estimate the relative influence by rBO, AD and allergic sensitisation on QoL₂, we calculated the percent point change equivalent to the difference in score for each QoL domain, given per nmol/L change in cortisol. For comparison, we calculated the difference in each QoL domain score that was attributed to a difference in salivary cortisol level of 95th versus 5th percentile (QoL score at the salivary cortisol level of 95th percentile minus QoL score at the 5th percentile). Salivary cortisol was studied as a continuous variable, and presented graphically by quartiles.

Each atopic manifestation was included in robust regression models to assess their potential influence on both cortisol and QoL₂, as well as the associations between the two (see Figure 2, hypothesis). For graphical presentations of QoL versus cortisol levels and cortisol levels versus atopic manifestations we used data unadjusted for age and gender. In line with previously demonstrated associations between morning salivary cortisol and age as well as gender (13), we decided a priori to analyse age and gender adjusted associations between cortisol and QoL as well between QoL and atopic manifestations. The

226 atopic manifestations were not considered to be confounders, as they could be causally associated with
227 both cortisol and QoL₂.

228 **Legend Figure 2:**

229 Directed acyclic graph showing hypothesised influence on cortisol and QoL_{24m} by allergic diseases
230 above the red line, and observed influence in the bronchiolitis group below the red line. The red line
231 indicates the net result from the influence of allergic disease on the association between morning
232 salivary cortisol and QoL_{24m}

233

234 Using QoL₂ as dependent variable in two-way regression analyses, we tested for interactions between
235 the group affiliation (bronchiolitis or controls) and cortisol, as well as between atopic manifestations
236 and cortisol. Due to interactions between group affiliation and salivary cortisol as well as atopic
237 dermatitis, analyses were stratified by group affiliation.

238 Possible confounding was assessed by robust regression and considered relevant if the outcome of the
239 model was changed by at least 25% (31) by any of the possible confounders (socioeconomic factors,
240 parental allergic disease, secondary smoke). Confounding by socioeconomic factors was tested by
241 including these factors in multiple regression models, and eliminating the factors with highest p-values
242 stepwise by Hosmer's procedure (31) until only factors with p-values < 0.05 remained, retaining age
243 and gender.

244 The level of statistical significance was set to $p < 0.05$ for all analyses.

245 Analyses were performed with the IBM SPSS Statistics 21 (IBM Corporation, Armonk, New York,
246 USA), and the NumberCruncher Statistical System (NCSS Kaysville, Utah, USA), version 11.

RESULTS

Atopic manifestations and QoL₂; bronchiolitis group vs. controls

Children in the bronchiolitis group were significantly more often affected by at least one atopic manifestation at two years and had more often rBO than the controls, while AD was similar in the two groups (Table 1).

The QoL₂ scores varied from 0-100 in five domains, with the smallest score range seen in the domain Getting along (53.3), as shown in Table 2. The bronchiolitis group reported larger improvement in health (Change in health), while controls scored significantly higher for Overall health and General health (Table 2).

Table 2

Unadjusted weighted means (95% CI) of QoL at two years of age (QoL_{24m}) of children included at hospitalisation for acute bronchiolitis and control children

Domain	Previous bronchiolitis	Control children	All children
	Unadjusted weighted means (95% CI)		Median (min, max)
Overall health	83.4 (81.3, 85.5)**	88.7 (86.3, 91.1)	85.0 (0.0, 100.0)
Physical abilities	100.0 (100.0, 100.0)	100.0 (100.0, 100.0)	100.0 (0.0, 100.0)
Growth and development	94.7 (93.7, 95.6)	95.2 (94.1, 96.3)	97.2 (0.0, 100.0)
Bodily pain/ discomfort	80.5 (78.4, 82.6)	78.5 (76.0, 80.9)	75.0 (8.3, 100.0)
Temperament and moods	84.2 (83.0, 85.4)	83.0 (81.7, 84.4)	84.7 (36.8, 100.0)
General behaviour	84.5 (82.9, 86.0)	85.2 (83.4, 86.9)	85.4 (35.4, 100.0)
Overall behaviour	85.0 (85.0, 85.0)	85.0 (85.0, 85.0)	85.0 (30.0, 100.0)
Getting along	78.8 (77.6, 80.0)	78.5 (77.2, 79.9)	78.3 (45.0, 98.2)
General health	67.1 (65.0, 69.2)****	78.3 (75.9, 80.7)	75.0 (18.2, 100.0)
Change in health	65.2 (62.8, 67.8)****	56.9 (54.1, 59.7)	50.0 (0.0, 100.0)
Parental impact – emotions	91.3 (90.1, 92.6)	91.3 (89.9, 92.7)	92.9 (35.7, 100.0)
Parental impact – time	95.2 (94.2, 96.1)	94.2 (93.1, 95.3)	95.2 (28.6, 100.0)
Family cohesion	79.6 (77.3, 82.0)	80.8 (78.1, 83.5)	85.0 (0.0, 100.0)

****p<0.0001

Quality of life and salivary cortisol at two years of age

In the bronchiolitis group, eight QoL₂ domains were significantly and positively associated with

265 morning salivary cortisol ($p=0.0001$ - $p=0.035$), see Table 3 and Figure 3. The association between
266 Overall health and salivary cortisol was significant only in boys, ($p<0.0001$).

267 **Table 3**

268 The potential influence of recurrent bronchial obstruction (rBO), atopic dermatitis (AD) and allergic
269 sensitisation (AS) on the associations between Quality of Life (QoL₂) and salivary cortisol at two years
270 of age is shown for 203 children who had moderate to severe acute bronchiolitis in infancy.

271 The influence by including each atopic manifestation (rBO, AD and AS) is shown as the percentage
272 change of QoL per 1 nmol/L change in salivary cortisol, adjusted for age and gender. Each column
273 includes all children with the observed atopic manifestation, and they are not mutually exclusive.

Domain (Mean domain score difference ¹ by difference between 95 th and 5 th percentile of cortisol, 51.6 nmol/L)	Change in QoL ₂ score per nmol/L unit salivary cortisol	rBO % change in association	AD	Allergic sensitisation
Overall health ² boys (16.0)	0.31 (0.17, 0.45)***	-20.7	-2.1	-0.5
Overall health girls (-0.0)	-0.00 (-0.16, 0.16)			
Growth and development (3.8)	0.07 (0.02, 0.13)**	-1.4	1.7	0.6
Bodily pain/ discomfort (6.2)	0.12 (0.01, 0.23)*	-8.3	5.4	-2.3
Temperament and moods (6.1)	0.12 (0.06, 0.18)***	-6.9	1.4	-1.5
General behaviour (4.6)	0.09 (0.01, 0.17)*	-6.7	-1.5	1.3
Getting along (4.0)	0.08 (0.02, 0.13)**	-3.0	-0.3	0.9
General health (5.6)	0.11 (-0.00, 0.22) ³	-26.9	0.4	0.3
Parental impact –Emotions (4.5)	0.09 (0.3, 0.15)**	-6.1	-5.1	1.2
Parental impact – Time (3.0)	0.06 (0.01, 0.10)*	-7.7	-0.1	0.9

274 ¹QoL score difference equals percentage point difference.

275 ²Overall health was gender stratified due to interaction.

276

277 * $p<0.05$ ** $p<0.01$ *** $p<0.001$ **** $p<0.0001$

278 ³ $p=0.0517$

279

280 **Legend Figure 3:**

281 Bronchiolitis group: QoL₂ scores for each domain, unadjusted, for each quartile of morning salivary
282 cortisol, 1st quartile lowest cortisol, 4th quartile highest. Due to interaction between gender and cortisol
283 for the Overall health domain, this domain was analysed separately for the genders. An association was
284 found only for boys for this domain. For Overall health, results for boys are shown. For the other
285 domains, results for both genders analysed together are shown.

286

287

288 In the controls, General health only was significantly associated with cortisol. The significant increase
289 of 0.1 percentage point per nmol/L in cortisol level (95% CI 0.0, 0.2, $p=0.046$) corresponded to a QoL₂
290 difference of five percent points between children having cortisol levels at the 5th vs 95th percentile (a
291 difference of 51.6 nmol/L of salivary cortisol). No further analyses were performed in this group, with
292 only one QoL domain significantly associated with salivary cortisol.

293 The hypothesised (top) and observed (bottom) influence of atopic manifestations on cortisol and QoL₂
294 are shown schematically in Figure 2. As shown in Table 2, the strongest influence on the associations
295 between cortisol and QoL₂ was exerted by rBO, reducing the associations with 1.4 to 26.9 per cent,
296 followed by changes related to AD ranging from -5.5 to 5.1 and less than 3 per cent changes by allergic
297 sensitisation. However, all associations between QoL and cortisol remained significant after including
298 rBO, AD and allergic sensitisation into the regression analyses.

299 Finally, we found no significant confounding effect of socioeconomic factors, parental ethnicity and
300 second-hand smoke at two years of age, and these were consequently not included in the final
301 multivariate analyses (see Supporting Information, Table 4 for details).

302

Table 4

Bronchiolitis group: Change of associations between salivary morning cortisol at and QoL24m at two years of age by socioeconomic factors, including age, gender, and the following socioeconomic factors: mother's education, father's education, mother's income, father's income, ethnicity of father and of mother (Caucasian or not) and secondhand smoke exposure at two years of age. The socioeconomic factors have been eliminated by Hosmer's stepdown procedure, finally retaining factors with $p < 0.05$. Age and gender have been retained in the models

Adjusted for/domain	Change of QoL score per nmol/L changed salivary cortisol after adjustment	% influence on change of QoL score by adjustment	Socioeconomic factors retained in the model
Overall Health	0.15 (0.05, 0.26)**	-16.7%	Caucasian father ¹ ****
Growth and Development	0.07 (0.02, 0.13)*	-3.7%	Caucasian father ¹ *
Bodily Pain/ Discomfort	0.12 (0.01, 0.23)*		All factors insignificant; eliminated from model
Temperament and Moods	0.11 (0.05, 0.17)***	-8.1%	Caucasian mother ¹ **
General Behaviour	0.08 (0.00, 0.16)*	-10.9%	Caucasian mother ¹ **
Getting Along	0.06 (0.01, 0.12)*	-18.8%	Education mother ¹ *, education father ² *, Caucasian mother ¹ **
Parental Impact -Emotions	0.08 (0.02, 0.14)*	-11.7%	Income father ¹ *, Caucasian mother ¹ ****
Parental Impact - Time	0.05 (0.01, 0.10)*	-13.1%	Caucasian mother ¹ *, Caucasian father ¹ **

¹ positively associated with QoL domain

² negatively associated with QoL domain

* $p < 0.05$ ** $p < 0.01$ *** $p < 0.001$ **** $p < 0.0001$

Salivary cortisol in bronchiolitis group vs. controls, and atopic manifestations

The age and gender adjusted salivary cortisol levels at two years were similar in the bronchiolitis group and controls. Weighted mean difference was -0.70 (95% CI -3.7, 2.3) nmol/L.

Salivary cortisol was significantly lower in children with rBO vs. children without rBO for the bronchiolitis group and controls together (weighted mean difference -4.1 (95%CI -7.3,-1.0) nmol/L), as shown schematically in Figure 2, and in unadjusted analysis in Figure 4. Neither AD nor allergic sensitisation was significantly associated with morning salivary cortisol at two years of age (Figures 1 and 3).

Legend Figure 4:

Morning salivary cortisol in children of the bronchiolitis group and controls together, without recurrent bronchial obstruction (rBO), defined as at least three wheeze episodes, compared to with rBO, no atopic dermatitis (AD) vs. with AD as well as with no or any positive skin prick test (SPT) to common inhalant and food allergens.

QoL₂ and atopic manifestations

The QoL₂ was significantly associated with rBO and AD in the bronchiolitis group, and with rBO as well as allergic sensitisation in the controls, as shown in Table 5, referring to absolute changes (= percentage point changes) in QoL₂ scores by the atopic diseases.

334 **Table 5**

335 **The impact of allergic diseases on QoL₂ is given for each domain as mean (95% CI), adjusted for age and**
 336 **gender, given for infants with moderate to severe bronchiolitis in infancy compared to controls.**

337 As an example; the negative association of General health (GH) with rBO is stronger in the bronchiolitis group
 338 than among controls, both being statistically significant.

339

	Recurrent bronchial obstruction		Atopic dermatitis		Allergic sensitisation	
	bronchiolitis group	controls	bronchiolitis group	controls	bronchiolitis group	controls
OH	-12.3 (-16.5, -8.2)****	-6.6 (-13.9, 0.7)	-5.5 (-11.7, 0.6)	-6.3 (-13.6, 0.9)	-0.7 (-8.6, 7.2)	-11.7 (-21.6, -1.9)*
PA	-1.2 (-2.1, -0.4)**	Not done ³	-0.0 (-0.0, 0.0)	-2.1 (-3.2, -1.0)***	0.0 (-0.2, 0.2)	Not done ⁷
GD	-3.5 (-5.8, -1.2)**	-1.3 (-4.3, 1.8)	-2.5 (-5.8, 0.7)	-1.2 (-4.2, 1.8)	-0.1 (-4.3, 4.0)	-1.9 (-6.4, 2.6)
BD	-6.5 (-10.8, -2.1)**	-7.3 (-14.7, 0.1)	-7.2 (-13.4, -0.9)*	-1.7 (-8.6, 5.3)	4.2 (-3.6, 12.1)	-6.4 (-16.8, 4.0)
TM	-3.1 (-5.5, -0.7)*	-4.1 (-7.8, -0.5)*	-5.1 (-8.4, -1.8)**	1.0 (-2.6, 4.5)	-2.5 (-1.8, 6.8)	-1.3 (-6.5, 3.9)
GB	-4.7 (-7.9, -1.4)**	-0.7 (-5.5, 4.1)	-5.3 (-9.9, -0.7)*	-4.1 (-8.8, 0.6)	-0.8 (-6.8, 5.2)	-7.0 (-13.7, -0.3)*
OB	-0.0 (-0.0, 0.0)	Not done ⁴	0.0 (0.0, 0.0)	Not done ⁵	0.0 (-0.0, 0.0)	Not done ⁷
GA	-1.9 (-4.2, 0.4)	-4.0 (-7.9, -0.0)*	-6.2 (-9.3, -3.0)***	-0.9 (-4.8, 2.9)	-0.4 (-4.6, 3.8)	-8.0 (-13.6, -2.4)**
GH	-13.8 (-17.8, -9.8)****	-6.8 (-12.9, -0.7)*	-5.8 (-12.0, 0.3)	-7.0 (-13.0, -1.0)*	0.1 (-7.9, 8.1)	-12.2 (-20.5, -3.9)**
CH	6.9 (0.8, 13.0)*	6.8 (-0.6, 14.2)	7.8 (-0.9, 16.4)	3.1 (-3.3, 9.6)	-1.0 (-12.3, 10.3)	7.3 (-2.8, 17.4)
PE	-4.0 (-6.4, -1.5)**	-2.3 (-5.9, 1.4)	-5.7 (-9.2, -2.2)**	-1.6 (-5.2, 2.0)	-0.2 (-4.7, 4.3)	-5.8 (-10.7, -1.0)*
PT	-2.5 (-4.5, -0.5)*	-2.1 (-5.0, 1.0)	-1.9 (-4.8, 1.0)	-1.9 (-4.9, 1.0)	-0.0 (-3.7, 3.7)	-4.3 (-8.3, -0.2)*
FC	-0.1 (-4.7, 4.5)	0.3 (-7.4, 8.0)	-5.4 (-11.9, 1.1)	0.7 (-6.7, 8.1)	-0.0 (-3.7, 3.7)	-1.8 (-12.3, 8.7)

340

341 ³Not done because gender is highly correlated with other X's ⁴Not done because rBO is highly correlated with
 342 other X's ⁵Not done because AD is highly correlated with other X's ⁶Not done, procedure call invalid ⁷Not
 343 done because AS is highly correlated with other X's

344

345 OH = Overall health; PA = Physical abilities; GD = Growth and development; BD = Bodily pain/ discomfort; TM
 346 = Temperament and moods; GB = General behaviour; OB = Overall behaviour; GA = Getting along; GH =
 347 General health; CH = Change in health; PE = Parental impact – emotions; PT = Parental impact – time; FC =
 348 Family cohesion

349

350 **Association between QoL₁ and salivary cortisol at two years**

351 In the bronchiolitis group only, QoL₁ was significantly and positively associated with morning salivary
 352 cortisol at two years of age in age and gender adjusted analysis for 8/13 domains, as shown in Table 6.

353

Table 6

Associations between QoL₁ (quality of life at a mean age of 14 months) scores and subsequent cortisol at visit 2, at a mean age of 24 months, bronchiolitis group only, adjusted for age at the two year old visit and gender.

	Change in cortisol nmol/L per QoL14m score change
Overall health	0.17 (0.02, 0.32)*
Physical abilities	0.92 (0.41, 1.43)***
Growth and development	0.34 (0.09, 0.60)**
Temperament and moods	0.35 (0.12, 0.59)**
General health	0.17 (0.01, 0.33)*
Parental impact - emotions	0.45 (0.19, 0.71)***
Parental impact - time	0.28 (0.11, 0.46)**

*p<0.05 **p<0.01 ***p<0.001

DISCUSSION

Quality of life was significantly associated with morning salivary cortisol at two years of age for most domains among children hospitalised with acute bronchiolitis in infancy, i.e. low cortisol was associated with low QoL, and high cortisol with high QoL. Significant associations were observed for the General Health domain only in controls. The associations remained significant, but were weakened by rBO, with only limited or no significant influence by AD or allergic sensitisation. The QoL in one-year old children was associated with salivary cortisol at two years of age.

We are not aware of other studies comparing QoL and morning salivary cortisol in children. Our findings that after moderate to severe acute bronchiolitis in infancy, QoL₂ was associated with salivary cortisol at two years of age, is to our knowledge novel. The results could not be confirmed in the population based controls. We have previously found that infants with acute bronchiolitis have higher morning salivary cortisol than controls (13), indicating acute stress. Others have found other signs of acute stress in acute bronchiolitis with respiratory syncytial virus, differing from other infections and acute diseases (32). Reduced QoL, found after acute bronchiolitis (5, 33), may partly be expressions of chronic stress, not only physical, but possibly psychological stress. Concerns of the parents of the children of the bronchiolitis group, as indicated by the Parental impact – emotions and Parental impact – time domains in the present study, seem to be associated with the children's cortisol levels. The associations that we found after acute bronchiolitis between cortisol and QoL in domains reflecting expressions of pain, moods and behaviour, i.e. Bodily pain/ discomfort, Temperament and moods, General behaviour and Getting along, partly influenced by rBO and AD, may also indicate a role of psychological stress in the development of atopic disease. Other studies have shown that pre- and postnatal maternal distress and negative life events are associated with allergic disease in children (19, 34). This may suggest long term effects on QoL of severe lower respiratory infection in infancy, possibly through chronic stress which has been negatively associated with morning cortisol (18, 35). The 16 percentage point difference in Overall health in boys with low versus high salivary cortisol is likely to be clinically relevant as they are comparable to the eight percentage point General health

396 differences between children with and without asthma-like symptoms reported from the Generation R
397 study (36).

398 The observed association between Overall health and morning salivary cortisol at two years of age was
399 significant among both genders analysed together, but only in boys by gender stratified analyses. This
400 may be explained by our significantly higher salivary cortisol levels in girls compared to boys in the
401 Bronchiolitis ALL study reported previously (13).

402 The influence by rBO, and to a lesser extent AD, on the associations between QoL and salivary cortisol
403 in children who were hospitalised for acute bronchiolitis in infancy in our study point to complex
404 associations between allergic diseases, QoL and salivary cortisol. This is in line with attenuated
405 regulation of the HPA axis previously shown in children with chronic atopic diseases, with a reduced
406 cortisol after acute stress provocation, indicating chronic stress (16, 19, 35, 37) and reduced morning
407 salivary cortisol observed in adults (23) and children (18) with poor asthma control. Our previous
408 findings of increased morning salivary cortisol during acute bronchiolitis in infancy (13) and reduced
409 QoL nine months later (7), were extended in the present study, showing that rBO, but not one episode of
410 bronchiolitis (13) was associated with lower morning salivary cortisol at two years of age. This may
411 indicate that repeated episodes of bronchial obstruction are necessary to affect cortisol levels, possibly
412 through chronic stress (13, 15, 19), irrespective of current use of inhaled corticosteroids (23). On the
413 other hand, our study was not designed to identify the reverse possibility of a potential causal role of
414 low salivary cortisol levels outside acute respiratory disease for the development of recurrent bronchial
415 obstruction.

416 The influence of AD on the associations between QoL and cortisol in our study was less clear, possibly
417 because most children with AD had mild disease. However, supporting our findings of some influence
418 on the cortisol-QoL association, Stenius et al. reported higher morning salivary cortisol in two year old
419 children with atopic dermatitis as opposed to children with recurrent wheeze who had a non-significant
420 tendency to lower salivary cortisol (22). The possible opposite association between rBO and AD with
421 cortisol in early childhood is not clear, since both diseases have been associated with reduced QoL.

422 The lack of significant associations between allergic sensitisation and QoL in the bronchiolitis group
 423 and allergic sensitisation and salivary cortisol may have several explanations. In our study less than 10
 424 per cent of the subjects were sensitised to at least one allergen, limiting the likelihood of observing
 425 significant associations. On the other hand, allergic sensitisation may not affect QoL before allergen
 426 exposure causes symptoms, which for inhalant allergens occur more frequently with increasing age (38).

427 Our finding that reduced QoL about one year of age was associated with lower salivary cortisol at two
 428 years of age is to our knowledge also novel. We recently showed in the same study population that in
 429 addition to having been hospitalised for acute bronchiolitis, disease severity and asthma risk factors as
 430 well as AD were associated with reduced QoL at 14 months of age (7, 8).

431 The direct clinical implications of our findings remain unclear at present. The influence by our asthma
 432 proxy of rBO dominated the association between QoL and salivary cortisol, weakening most of the
 433 associations by more than five per cent. This finding is supported by a stronger influence by the total
 434 number of wheeze episodes, as shown in the Supporting Information. The maintenance of statistical
 435 significance of the influence of cortisol on QoL after including rBO in the regression model also
 436 indicates an additive negative effect of low cortisol and rBO on QoL. The implications in terms of the
 437 Overall health domain could be shown by a 24-months-old boy with rBO and low salivary cortisol, at
 438 the 5th percentile, having an estimated 23.1 percentage point lower QoL than a boy without rBO who
 439 had a high salivary cortisol level, at the 95th percentile. However, our study suggests that in addition to
 440 rBO and to some extent AD, also acute moderate to severe infant bronchiolitis may play a role in the
 441 association between future salivary cortisol and QoL. Although acute infant bronchiolitis per se may not
 442 lead to future low cortisol levels, QoL was reduced both at 14 and 24 months of age compared to
 443 controls. Although the influence of the asthma proxy of at least three episodes of bronchial obstruction
 444 in our study dominated the association between cortisol and QoL at two years, the associations were
 445 significant also among children in the bronchiolitis group who did not go on to develop rBO, as shown
 446 in Supporting Information. Together these observations suggest that children who have acute
 447 bronchiolitis in infancy and reduced QoL some months later may be at increased risk of chronic stress,

observed by lower salivary cortisol and reduced QoL at two years of age. Thus, our study support a role of chronic stress indicated by lower cortisol levels in development of asthma, but with unclear links to atopic dermatitis and allergic sensitisation in young children.

In line with previous studies finding marginally lower cortisol in adolescents with low socioeconomic status (39), we included socioeconomic data as well as second-hand smoking into regression analyses. However, none of these factors were found to be significant confounders, possibly reflecting the overriding effects by atopic diseases in the children, as well as a low frequency of second-hand smoke in our cohort.

Strengths and limitations

The study strengths include a prospective design of a reasonably large group of children included in infancy with and without acute bronchiolitis and atopic disease, a high rate of follow-up investigations, repeated measurements and stringent clinical characterisation of the subjects. Also, the findings appear robust, as the associations remained significant after relevant adjustments.

The lack of significant associations between QoL and salivary cortisol in the control group may be due to the relatively few subjects with recurrent bronchial obstruction, shown to be most consistently associated with reduced QoL and salivary cortisol, and that the control children may be more heterogeneous, possibly with a lower risk of future asthma development, or that the control children in general had a higher QoL.

As previously reported (7, 8), we decided a priori not to adjust for multiple analyses, as the QoL domains were not independent from each other. Also, the associations with the different QoL domains point in the same direction, limiting the likelihood of incidental findings. The only domain pointing in the opposite direction was Change in health, where a lower score reflects less improvement from an earlier time point. This domain has been shown to be higher in children with chronic diseases than general population children (5), and was the only domain with higher scores in the bronchiolitis than the control group in our study.

The rate of AD and allergic sensitisation was high among the controls, possibly reflecting that parents with some atopic manifestation were more likely to enrol their child into the study.

The use of a single morning salivary cortisol measurement to improve feasibility of a high data collection may be a limitation of our study. However, previous studies of single morning measurements (18) and the lack of significant day-to-day variation between three samples taken at 4- to 8-day intervals (40), suggest that single measures may reflect the habitual morning cortisol state. Also, we sampled as soon as possible after the first awakening after 6:00 a.m. (13), to encompass a possible morning awakening response and the top circadian morning value (25).

Conclusion

At two years of age QoL was positively associated with morning salivary cortisol in children who had undergone moderate to severe acute bronchiolitis in infancy. The associations were influenced by recurrent bronchial obstruction and, to a limited extent, by atopic dermatitis. The QoL in one-year-old children was associated with salivary cortisol 10 months later.

ACKNOWLEDGEMENTS

We warmly acknowledge all participating children and parents and the members of the Bronchiolitis Study Group, and study nurses, see Supporting Information, and the several hundred study staff that were involved in recruiting patients and running the study. Warm thanks also to Johan Alm and Ann-Christine Sjöbeck, Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden, for the analysis of the salivary cortisol samples.


References

1. Lang A, Mowinckel P, Sachs-Olsen C, Riiser A, Lunde J, Carlsen KH, et al. Asthma severity in childhood, untangling clinical phenotypes. *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*. 2010;21(6):945-53.

2. Everhart RS, Fiese BH. Asthma severity and child quality of life in pediatric asthma: a systematic review. *Patient Educ Couns*. 2009;75(2):162-8.
3. Chamlin SL, Chren MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. *Immunol Allergy Clin North Am*. 2010;30(3):281-8.
4. Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. *The Pediatric infectious disease journal*. 2004;23(5):414-7.
5. Spuijbroek AT, Oostenbrink R, Landgraf JM, Rietveld E, de Goede-Bolder A, van Beeck EF, et al. Health-related quality of life in preschool children in five health conditions. *Qual Life Res*. 2011;20(5):779-86.
6. Backman K, Piippo-Savolainen E, Ollikainen H, Koskela H, Korppi M. Increased asthma risk and impaired quality of life after bronchiolitis or pneumonia in infancy. *Pediatric pulmonology*. 2014;49(4):318-25.
7. Rolfsjord LB, Skjerven HO, Bakkeheim E, Carlsen KH, Hunderi JO, Kvenshagen BK, et al. Children hospitalised with bronchiolitis in the first year of life have a lower quality of life nine months later. *Acta paediatrica (Oslo, Norway : 1992)*. 2015;104(1):53-8.
8. Rolfsjord LB, Skjerven HO, Carlsen KH, Mowinckel P, Bains KE, Bakkeheim E, et al. The severity of acute bronchiolitis in infants was associated with quality of life nine months later. *Acta paediatrica (Oslo, Norway : 1992)*. 2016;105(7):834-41.
9. Carlsen KH, Larsen S, Orstavik I. Acute bronchiolitis in infancy. The relationship to later recurrent obstructive airways disease. *Eur J Respir Dis*. 1987;70(2):86-92.
10. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. *Thorax*. 2010;65(12):1045-52.
11. Raat H, Landgraf JM, Oostenbrink R, Moll HA, Essink-Bot ML. Reliability and validity of the Infant and Toddler Quality of Life Questionnaire (ITQOL) in a general population and respiratory disease sample. *Qual Life Res*. 2007;16(3):445-60.
12. Bhandari P. Stress and health related quality of life of Nepalese students studying in South Korea: a cross sectional study. *Health Qual Life Outcomes*. 2012;10:26.
13. Rolfsjord LB, Bakkeheim E, Berents TL, Alm J, Skjerven HO, Carlsen KH, et al. Morning Salivary Cortisol in Young Children: Reference Values and the Effects of Age, Sex, and Acute Bronchiolitis. *The Journal of pediatrics*. 2017;184:193-8.e3.
14. Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, Kirschbaum C. HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. *Psychoneuroendocrinology*. 2004;29(1):83-98.
15. Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Diaz PV. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. *Pediatrics*. 2006;117(5):e878-86.
16. Buske-Kirschbaum A. Cortisol responses to stress in allergic children: interaction with the immune response. *Neuroimmunomodulation*. 2009;16(5):325-32.
17. Hu C, Li Z, Feng J, Tang Y, Qin L, Hu X, et al. Glucocorticoids Modulate Th1 and Th2 Responses in Asthmatic Mouse Models by Inhibition of Notch1 Signaling. *International archives of allergy and immunology*. 2018;175(1-2):44-52.
18. Bakkeheim E, Mowinckel P, Carlsen KH, Burney P, Lodrup Carlsen KC. Reduced basal salivary cortisol in children with asthma and allergic rhinitis. *Acta paediatrica (Oslo, Norway : 1992)*. 2010;99(11):1705-11.
19. Dreger LC, Kozyrskyj AL, HayGlass KT, Becker AB, MacNeil BJ. Lower cortisol levels in children with asthma exposed to recurrent maternal distress from birth. *The Journal of allergy and clinical immunology*. 2010;125(1):116-22.
20. Wolf JM, Nicholls E, Chen E. Chronic stress, salivary cortisol, and alpha-amylase in children with asthma and healthy children. *Biological psychology*. 2008;78(1):20-8.
21. Kojima R, Matsuda A, Nomura I, Matsubara O, Nonoyama S, Ohya Y, et al. Salivary cortisol response to stress in young children with atopic dermatitis. *Pediatr Dermatol*. 2013;30(1):17-22.
22. Stenius F, Borres M, Bottai M, Lilja G, Lindblad F, Pershagen G, et al. Salivary cortisol levels and allergy in children: the ALADDIN birth cohort. *The Journal of allergy and clinical immunology*. 2011;128(6):1335-9.
23. Shin YS, Liu JN, Kim JH, Nam YH, Choi GS, Park HS. The impact of asthma control on salivary cortisol level in adult asthmatics. *Allergy, asthma & immunology research*. 2014;6(5):463-6.
24. Gozansky WS, Lynn JS, Laudenslager ML, Kohrt WM. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic--pituitary--adrenal axis activity. *Clinical endocrinology*. 2005;63(3):336-41.

25. Ivars K, Nelson N, Theodorsson A, Theodorsson E, Strom JO, Morelius E. Development of Salivary Cortisol Circadian Rhythm and Reference Intervals in Full-Term Infants. *PloS one*. 2015;10(6):e0129502.
26. Skjerven HO, Hunderi JO, Brugmann-Pieper SK, Brun AC, Engen H, Eskedal L, et al. Racemic adrenaline and inhalation strategies in acute bronchiolitis. *N Engl J Med*. 2013;368(24):2286-93.
27. Skjerven HO, Rolfjord LB, Berents TL, Engen H, Dizdarevic E, Midgaard C, et al. Allergic diseases and the effect of inhaled epinephrine in children with acute bronchiolitis: follow-up from the randomised, controlled, double-blind, Bronchiolitis ALL trial. *Lancet Respir Med*. 2015;3(9):702-8.
28. Hanifin JM RG. Diagnostic features of atopic dermatitis. *Acta Derm Venereol*. 1980;92:44-7.
29. Oostenbrink R, Jansingh-Piepers EM, Raat H, Nuijsink M, Landgraf JM, Essink-Bot ML, et al. Health-related quality of life of pre-school children with wheezing illness. *Pediatric pulmonology*. 2006;41(10):993-1000.
30. Hamilton L. Regression with graphics. A second course in applied statistics. Pacific Grove, California, USA: Brooks/Cole Publishing Company; 1991.
31. Hosmer DW. Applied logistic regression. In: S L, editor. 2 nd ed. Hoboken, NJ, USA: John Wiley and sons; 2000.
32. Yoshida S, Noguchi A, Kikuchi W, Fukaya H, Igarashi K, Takahashi T. Elevation of Serum Acid Sphingomyelinase Activity in Children with Acute Respiratory Syncytial Virus Bronchiolitis. *The Tohoku journal of experimental medicine*. 2017;243(4):275-81.
33. Rolfjord LB, Skjerven HO, Bakkeheim E, Berents TL, Mowinckel P, Carlsen K-H, et al. Quality of Life, Salivary Cortisol and Allergic Diseases in Young Children; is there a Link? 2017.
34. Lee A, Mathilda Chiu YH, Rosa MJ, Jara C, Wright RO, Coull BA, et al. Prenatal and postnatal stress and asthma in children: Temporal- and sex-specific associations. *The Journal of allergy and clinical immunology*. 2016.
35. Priftis KN, Papadimitriou A, Nicolaidou P, Chrousos GP. Dysregulation of the stress response in asthmatic children. *Allergy*. 2009;64(1):18-31.
36. Mohangoo AD, de Koning HJ, de Jongste JC, Landgraf JM, van der Wouden JC, Jaddoe VW, et al. Asthma-like symptoms in the first year of life and health-related quality of life at age 12 months: the Generation R study. *Qual Life Res*. 2012;21(3):545-54.
37. Buske-Kirschbaum A, Jobst S, Wustmans A, Kirschbaum C, Rauh W, Hellhammer D. Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis. *Psychosomatic medicine*. 1997;59(4):419-26.
38. Halken S. Early sensitisation and development of allergic airway disease - risk factors and predictors. *Paediatr Respir Rev*. 2003;4(2):128-34.
39. Chen E, Fisher EB, Bacharier LB, Strunk RC. Socioeconomic status, stress, and immune markers in adolescents with asthma. *Psychosomatic medicine*. 2003;65(6):984-92.
40. Nagakura T, Tanaka T, Arita M, Nishikawa K, Shigeta M, Wada N, et al. Salivary cortisol monitoring: determination of reference values in healthy children and application in asthmatic children. *Allergy Asthma Proc*. 2012;33(4):362-9.

Figure 2



Figure

Figure 3




Figure 4




Figure 1

